Related Experiment Videos
[Apoptosis--programmed cell death]
1Oddĕlení klinické hematologie 1. LF UK a VFN, Praha.
Casopis Lekaru Ceskych
|May 3, 1995
Abstract:
The authors summarize findings on apoptosis-programmed cellular death, incl. basic data on expression of genes promoting (p53, c-myc, MTS 1 and fas) or inhibiting (bcl-2, bcr-abl) this process. The authors discuss clinical possibilities of controlling apoptosis, in particular in oncology and in autoimmune disease, AIDS, metabolic disorders etc.
Insights
This study reviews programmed cell death (apoptosis) gene expression, covering both pro-apoptotic and anti-apoptotic factors. It explores therapeutic strategies for controlling apoptosis in diseases like cancer and AIDS.
Area of Science:
- Molecular Biology
- Genetics
- Cell Biology
Context:
- Apoptosis, or programmed cell death, is a fundamental biological process.
- Dysregulation of apoptosis is implicated in various diseases, including cancer, autoimmune disorders, and viral infections.
- Understanding the genetic control of apoptosis is crucial for therapeutic interventions.
Purpose:
- To summarize current knowledge on the genes regulating apoptosis.
- To discuss the clinical implications of manipulating apoptotic pathways.
- To highlight potential therapeutic targets for controlling programmed cell death.
Summary:
- The review covers genes that promote apoptosis, such as p53, c-myc, MTS1, and Fas.
- It also addresses genes that inhibit apoptosis, including bcl-2 and bcr-abl.
- The authors examine the clinical applications of modulating apoptosis in oncology, autoimmune diseases, AIDS, and metabolic disorders.
Impact:
- Provides a comprehensive overview of apoptosis regulation.
- Identifies potential strategies for novel therapeutic approaches.
- Facilitates a deeper understanding of disease mechanisms linked to apoptosis dysregulation.